DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
KB003
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
KB003
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROLEDUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Blood group Rh(D) polypeptide inhibitor
ROLEDUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
Z4T52O86QV
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANETUMAB RAVTANSINE
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasms; Pancreatic Neoplasms
Mesothelin binding agent
ANETUMAB RAVTANSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
M170940PMI
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZAGOTENEMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease
Microtubule-associated protein tau inhibitor
ZAGOTENEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AY6V5E2GNX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PATECIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PATECIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SABIRNETUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SABIRNETUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SIBEPRENLIMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SIBEPRENLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BAFISONTAMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
BAFISONTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRECEMTABART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PRECEMTABART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CIFURTILIMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
CIFURTILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IRATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Lymphoma; Hematologic Neoplasms; Hodgkin Disease
Tumor necrosis factor receptor superfamily member 8 other
IRATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AYH22O1B1U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZILTIVEKIMAB
2
Antibody
Investigational
Unknown
Unknown
Anemia; Renal Insufficiency, Chronic
Interleukin-6 binding agent
ZILTIVEKIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AN3Y2B4SX4
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NAVENIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
NAVENIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GANCOTAMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms
DNA inhibitor
GANCOTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
S5Z216QNO6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CANRIVITUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
CANRIVITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
QUILIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Rhinitis, Allergic, Seasonal; Asthma; Urticaria
Ig epsilon chain C region inhibitor
QUILIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
26F96HRJ3W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TGN-1412
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Neoplasms; Psoriasis; Lupus Erythematosus, Systemic
T-cell-specific surface glycoprotein CD28 agonist
TGN-1412
×
Maximum Phase:
2
First Approval:
None
UNII:
POO0DOD3AS
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ORTICUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Oxidized LDL inhibitor
ORTICUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
2O892R8U24
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIIB-023
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Nephritis
Tumor necrosis factor ligand superfamily member 12 inhibitor
BIIB-023
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SENIPRUTUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SENIPRUTUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ONCOLYSIN B
2
Antibody
Investigational
Unknown
Unknown
Unknown
B-lymphocyte antigen CD19 binding agent
ONCOLYSIN B
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RINATABART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
RINATABART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZERIPATAMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ZERIPATAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMELCIMENT
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
IMELCIMENT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TILAVONEMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease; Supranuclear Palsy, Progressive
Microtubule-associated protein tau inhibitor
TILAVONEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
MY9Z7GDJ8J
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TUVIRUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Major surface antigen inhibitor
TUVIRUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
31Z0AB5WNC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VILASTOBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
VILASTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GEDIVUMAB
2
Antibody
Investigational
Unknown
Unknown
Influenza, Human
Hemagglutinin inhibitor
GEDIVUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
6IRE1TI49I
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZENOCUTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms
ErbB-2/ErbB-3 heterodimer inhibitor
ZENOCUTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AE72RB1W1X
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMZOKITUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
IMZOKITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TENELIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Tumor necrosis factor receptor superfamily member 5 partial agonist
TENELIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
G0MV33WQ6V
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
YTTRIUM Y 90 CAPROMAB PENDETIDE
2
Antibody
Investigational
Unknown
Unknown
Unknown
Glutamate carboxypeptidase II binding agent
YTTRIUM Y 90 CAPROMAB PENDETIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EXLINKIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
EXLINKIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-522
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MEDI-522
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAMATATUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SAMATATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
16
17
18
19
20
21
22
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA